Bristol-Myers Squibb Aktie
| 57,85USD | -0,04USD | -0,06% |
WKN: 850501 / ISIN: US1101221083
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99,92 |
| The Vanguard Group, Inc. | 9,77 |
| Vanguard Group, Inc. (Subfiler) | 8,83 |
| State Street Corp. | 4,58 |
| Vanguard Total Stock Market ETF | 3,17 |
| Charles Schwab Investment Management, Inc. | 3,01 |
| BlackRock Fund Advisors | 2,92 |
| Vanguard 500 Index Fund | 2,62 |
| JPMorgan Investment Management, Inc. | 2,49 |
| Schwab US Dividend Equity ETF | 2,45 |
| BlackRock Institutional Trust Co. NA | 2,23 |
| Geode Capital Management LLC | 2,13 |
| Capital Research & Management Co. (International Investors) | 2,10 |
| Norges Bank (13F) | 1,61 |
| Fidelity 500 Index Fund | 1,23 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 30 000 | 30 250 | 32 200 | 34 300 | 34 100 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,87 | 1,41 | 1,44 | 1,35 | 1,32 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 29 354 | 30 192 | 33 262 | 27 273 | 31 770 |
| Summe Anlagevermögen | 100 590 | 88 289 | 76 052 | 69 547 | 63 389 |
| Summe Aktiva | 129 944 | 118 481 | 109 314 | 96 820 | 95 159 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 47 538 | 51 673 | 45 596 | 40 717 | 41 464 |
| Summe Fremdkapital | 78 246 | 80 599 | 73 308 | 65 702 | 65 674 |
| Summe Eigenkapital | 51 698 | 37 882 | 36 006 | 31 118 | 29 485 |
| Summe Passiva | 129 944 | 118 481 | 109 314 | 96 820 | 95 159 |
Adresse
| Route 206 & Province Line Road, 08543 Princeton | |
| Telefon | +1 (609) 252-4621 |
| Internet | http://www.bms.com |
Management
|
Abed Al-Nasser Odeh
Manager |
|
Adam Lenkowsky
Chief Commercialization Officer & Executive VP |
|
Amanda Poole
Chief Human Resources Officer & Executive VP |
|
Amy Fallone
Secretary |
|
Cari Gallman
Executive Vice President-Corporate Affairs |
|
Catalina Vargas
Chief Of Staff |
|
Christopher S. Boerner
Chairman & Chief Executive Officer |
|
Cynthia Piccirillo
Group Director |
|
David V. Elkins
Chief Financial Officer & Executive Vice President |
|
Deepak L. Bhatt
Independent Director |
|
Derica W. Rice
Independent Director |
|
Estelle Vester-Blokland
Senior VP-Global Medical Affairs |
|
Frank Incontrera
Director-Global Energy Services |
|
Greg Meyers
Chief Digital & Technology Officer |
|
Julia A. Haller
Independent Director |
|
Karen H. Vousden
Independent Director |
|
Kimberly McCutcheon Jablonski
Chief Compliance & Ethics Officer |
|
Krisztina Nemenyi
Head-Asia Pacific Global Regulatory Affairs |
|
Laura Hortas
Head-Corporate & Employee Communications |
|
Louis S. Schmukler
President-Global Product Development & Supply |
|
MARIA V LOPEZ BRESNAHAN
Vice President |
|
Manuel Hidalgo Medina
Independent Director |
|
Mark Rolfe
Senior Vice President |
|
Melissa Seymour
Chief Quality Officer |
|
Michael R. McMullen
Independent Director |
|
Monica Shaw
Senior Vice President-Major Markets |
|
Paula A. Price
Independent Director |
|
Peter J. Arduini
Independent Director |
|
Phil Holzer
Senior Vice President & Controller |
|
Phyllis R. Yale
Independent Director |
|
Robert M. Plenge
Chief Research Officer, Head-Research & EVP |
|
Samit Hirawat
Chief Medical Officer & EVP-Drug Development |
|
Sandra Leung
Executive Vice President & General Counsel |
|
Teresa M. Foy
Senior VP-Immuno Oncology & Cell Therapy |
|
Theodore Rapp Samuels
Lead Independent Director |
|
William Perhacs
Director-Global Energy & Sustainability Services |
|
Zack Newman
Associate Director-Global Sustainability Strategy |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
